Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple MyelomaBlood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, precancerous condition, proteostasis deficiencies, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic diseaseRecruitingPhase 12026-09-25NCT06768489

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Janssen Research & Development, LLC188

16 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Calvary Mater Newcastle HospitalWaratahAustralia4
Carmel Medical CenterHaifaIsrael24
Colorado Blood Cancer InstituteDenverUnited States178
Hadassah Medical CenterJerusalemIsrael50
Hosp Clinico Univ de SalamancaSalamancaSpain34
Hosp. Clinic de BarcelonaBarcelonaSpain14
Monash Medical CentreClaytonAustralia16
Peter MacCallum Cancer CentreMelbourneAustralia32
Sheba Medical CenterRamat GanIsrael42
St Vincents Hospital MelbourneFitzroyAustralia14
Tel Aviv Sourasky Medical CenterTel AvivIsrael43
UMC UtrechtUtrechtNetherlands30
Universitair Medisch Centrum GroningenGroningenNetherlands49
VU Medisch CentrumAmsterdamNetherlands16
Winship Cancer Institute Emory UniversityAtlantaUnited States11
Wollongong HospitalWollongongAustralia6